CMB: Adjusted revenue and profit forecasts for Ali Health (00241.HK) have been raised, with the target price increased to HK$6.5.

According to the Wise Finance APP, JPMorgan Chase released a research report stating that the stock price of Ali Health (00241.HK) has increased by approximately 27% after the announcement of its financial performance for the 2025 fiscal year in May, exceeding its industry peers by 8 percentage points. The bank believes that this is mainly due to investors' positive response to recent updates in the policy for online retail sales of prescription drugs. The target price has been raised from 5 Hong Kong dollars to 6.5 Hong Kong dollars, equivalent to a predicted market-to-sales ratio of 2.5 times for the current fiscal year, maintaining a "neutral" rating. Considering that this is basically a guideline with no substantial differences from existing policies, it is believed that its impact is more reflected on the emotional level.